The results of clinical sample detection show that FGFRL1 is overexpressed in small-cell lung cancer (SCLC) tissues, and high FGFRL1 expression is associated with the clinical stage, chemotherapy response, and survival time of SCLC patients. This evidence concerns the gene FGFRL1 and small cell lung carcinoma.